2295-31-0 | 2,4-Thiazolidinedione

Packsize	Purity	Availability	Price	Discounted Price
5g	97%	in stock	$10.00	$7.00
25g	95%	in stock	$17.00	$12.00
100g	95%	in stock	$24.00	$17.00
500g	95%	in stock	$34.00	$24.00

Description

• Catalog Number: AB21179
• Chemical Name: 2,4-Thiazolidinedione
• CAS Number: 2295-31-0
• Molecular Formula: C3H3NO2S
• Molecular Weight: 117.1264
• MDL Number: MFCD00005478
• SMILES: O=C1SCC(=O)N1
• NSC Number: 6745

Computed Properties

• Complexity: 122
• Covalently-Bonded Unit Count: 1
• Heavy Atom Count: 7
• Hydrogen Bond Acceptor Count: 3
• Hydrogen Bond Donor Count: 1
• XLogP3: 0.1

Literature

• Establishment of a novel mouse model for pioglitazone-induced skeletal muscle injury.

  Toxicology 20170501

• Kinetics of the Absorption, Distribution, Metabolism, and Excretion of Lobeglitazone, a Novel Activator of Peroxisome Proliferator-Activated Receptor Gamma in Rats.

  Journal of pharmaceutical sciences 20150901

• Synthesis of kifunensine thioanalogs and their inhibitory activities against HIV-RT and α-mannosidase.

  Carbohydrate research 20130110

• Density functional study on the cytochrome-mediated S-oxidation: identification of crucial reactive intermediate on the metabolic path of thiazolidinediones.

  The journal of physical chemistry. A 20121025

• Adiponectin and all-cause mortality in elderly people with type 2 diabetes.

  Diabetes care 20120901

• Synthesis, hypoglycemic and hypolipidemic activities of novel thiazolidinedione derivatives containing thiazole/triazole/oxadiazole ring.

  European journal of medicinal chemistry 20120701

• Effect of phosphatidylinositol 3-kinase-γ inhibitor CAY10505 in hypertension, and its associated vascular endothelium dysfunction in rats.

  Canadian journal of physiology and pharmacology 20120701

• Thiazolidinedione-dependent activation of sphingosine kinase 1 causes an anti-fibrotic effect in renal mesangial cells.

  British journal of pharmacology 20120601

• 5-benzylidenerhodanine and 5-benzylidene-2-4-thiazolidinedione based antibacterials.

  Bioorganic & medicinal chemistry letters 20120415

• Initiation of insulin among veterans with type 2 diabetes and sustained elevation of A1c.

  Primary care diabetes 20120401

• Peroxisome proliferator-activated receptors-α and -γ, and cAMP-mediated pathways, control retinol-binding protein-4 gene expression in brown adipose tissue.

  Endocrinology 20120301

• Effect of structural modifications on 3-(3,5-dichlorophenyl)-2,4-thiazolidinedione-induced hepatotoxicity in Fischer 344 rats.

  Journal of applied toxicology : JAT 20120201

• Targeting orphan nuclear receptors for treatment of metabolic diseases and autoimmunity.

  Chemistry & biology 20120127

• Privileged scaffolds or promiscuous binders: a comparative study on rhodanines and related heterocycles in medicinal chemistry.

  Journal of medicinal chemistry 20120126

• PPARgamma rescue of the mitochondrial dysfunction in Huntington's disease.

  Neurobiology of disease 20120101

• Synthesis and antihyperglycemic evaluation of new 2,4-thiazolidinediones having biodynamic aryl sulfonylurea moieties.

  Bioorganic & medicinal chemistry letters 20120101

• In vivo adipogenesis in rats measured by cell kinetics in adipocytes and plastic-adherent stroma-vascular cells in response to high-fat diet and thiazolidinedione.

  Diabetes 20120101

• New cholesterol esterase inhibitors based on rhodanine and thiazolidinedione scaffolds.

  Bioorganic & medicinal chemistry 20111215

• The role of PPARβ/δ in the management of metabolic syndrome and its associated cardiovascular complications.

  Endocrine, metabolic & immune disorders drug targets 20111201

• Comparison of the acute toxicities of novel algicides, thiazolidinedione derivatives TD49 and TD53, to various marine organisms.

  Environmental toxicology and chemistry 20111201

• Genetic predisposition and nongenetic risk factors of thiazolidinedione-related edema in patients with type 2 diabetes.

  Pharmacogenetics and genomics 20111201

• Effects of plane of nutrition and 2,4-thiazolidinedione on insulin responses and adipose tissue gene expression in dairy cattle during late gestation.

  Journal of dairy science 20111201

• Effects of prepartum 2,4-thiazolidinedione on insulin sensitivity, plasma concentrations of tumor necrosis factor-α and leptin, and adipose tissue gene expression.

  Journal of dairy science 20111101

• Antidiabetic actions of a non-agonist PPARγ ligand blocking Cdk5-mediated phosphorylation.

  Nature 20110922

• The dysfunction of hepatic transcriptional factors in mice with Huntington's Disease.

  Biochimica et biophysica acta 20110901

• Structure-activity relationship and docking studies of thiazolidinedione-type compounds with monoamine oxidase B.

  Bioorganic & medicinal chemistry letters 20110815

• Profibrinolytic, antithrombotic, and antiinflammatory effects of an insulin-sensitizing strategy in patients in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial.

  Circulation 20110809

• Synthesis of new chalcone derivatives bearing 2,4-thiazolidinedione and benzoic acid moieties as potential anti-bacterial agents.

  European journal of medicinal chemistry 20110801

• High-throughput kinase profiling: a more efficient approach toward the discovery of new kinase inhibitors.

  Chemistry & biology 20110729

• Efficacy and safety of saxagliptin combination therapy in US patients with type 2 diabetes.

  Postgraduate medicine 20110701

• Synthesis of spirocyclic thiazolidinediones using ring-closing metathesis and one-pot sequential ring-closing/cross metathesis.

  Organic & biomolecular chemistry 20110521

• Peroxisome proliferator-activated receptor-γ stimulates 11β-hydroxysteroid dehydrogenase type 1 in rat vascular smooth muscle cells.

  Steroids 20110501

• Changes and predictors for change to thiazolidinedione prescribing in UK primary care following the rosiglitazone safety warning.

  International journal of clinical practice 20110501

• [Effects of drugs for lifestyle-related diseases on bone metabolism].

  Clinical calcium 20110501

• [Pharmacotherapy of osteoporosis accompanied by lifestyle-related diseases].

  Clinical calcium 20110501

• Synthesis and biological evaluation of novel 5-benzylidenethiazolidine-2,4-dione derivatives for the treatment of inflammatory diseases.

  Journal of medicinal chemistry 20110414

• Thiazolidinedione use and ulcerative colitis-related flares: an exploratory analysis of administrative data.

  Inflammatory bowel diseases 20110301

• Interaction of phytochemicals with hypoglycemic drugs on glucose uptake in L6 myotubes.

  Phytomedicine : international journal of phytotherapy and phytopharmacology 20110215

• S-oxidation of thiazolidinedione with hydrogen peroxide, peroxynitrous acid, and C4a-hydroperoxyflavin: a theoretical study.

  The journal of physical chemistry. A 20110210

• Convenient synthesis of polyfunctional dihydrothiophenes with tandem reaction of 1,3-thiazolidinedione, aldehyde, arylamine and ethyl cyanoacetate.

  Molecular diversity 20110201

• Lipocalin 2 is a selective modulator of peroxisome proliferator-activated receptor-gamma activation and function in lipid homeostasis and energy expenditure.

  FASEB journal : official publication of the Federation of American Societies for Experimental Biology 20110201

• An arylidene-thiazolidinedione derivative, GPU-4, without PPARγ activation, reduces retinal neovascularization.

  Current neurovascular research 20110201

• Concomitant oral antihyperglycemic agent use and associated treatment outcomes after initiation of insulin therapy.

  Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists 20110101

• Thiazolidinedione therapy for managing metabolic syndrome.

  American family physician 20101215

• Thiazolidinediones as a novel class of algicides against red tide harmful algal species.

  Applied biochemistry and biotechnology 20101201

• Safety and tolerability of vildagliptin vs. thiazolidinedione as add-on to metformin in type 2 diabetic patients with and without mild renal impairment: a retrospective analysis of the GALIANT study.

  Diabetes research and clinical practice 20101101

• Modulation of energy deficiency in Huntington's disease via activation of the peroxisome proliferator-activated receptor gamma.

  Human molecular genetics 20101015

• Relationships between daily acute glucose fluctuations and cognitive performance among aged type 2 diabetic patients.

  Diabetes care 20101001

• Variation at the NFATC2 locus increases the risk of thiazolidinedione-induced edema in the Diabetes REduction Assessment with ramipril and rosiglitazone Medication (DREAM) study.

  Diabetes care 20101001

• Synthesis and primary cytotoxicity evaluation of new 5-benzylidene-2,4-thiazolidinedione derivatives.

  European journal of medicinal chemistry 20101001

• Effects of in vitro insulin and 2,4-thiazolidinedione on the function of neutrophils harvested from blood of cows in different physiological states.

  Journal of dairy science 20100901

• Colon OCTN2 gene expression is up-regulated by peroxisome proliferator-activated receptor gamma in humans and mice and contributes to local and systemic carnitine homeostasis.

  The Journal of biological chemistry 20100827

• Modulation of pantothenate kinase 3 activity by small molecules that interact with the substrate/allosteric regulatory domain.

  Chemistry & biology 20100827

• MCC-555-induced NAG-1 expression is mediated in part by KLF4.

  European journal of pharmacology 20100710

• Distinct association of serum FGF21 or adiponectin levels with clinical parameters in patients with type 2 diabetes.

  Diabetes research and clinical practice 20100701

• Bone loss and fracture risk associated with thiazolidinedione therapy.

  Pharmacotherapy 20100701

• A perspective on the American Heart Association/American College of Cardiology science advisory on thiazolidinedione drugs and cardiovascular risks.

  Circulation. Cardiovascular quality and outcomes 20100501

• [Revascularization in patients with type 2 diabetes and coronary artery disease: BARI 2D (Bypass Angioplasty Revascularization Investigation 2 Diabetes) Study Group].

  Der Internist 20100501

• Adherence to a fixed-dose combination of rosiglitazone/glimepiride in subjects switching from monotherapy or dual therapy with a thiazolidinedione and/or a sulfonylurea.

  The Annals of pharmacotherapy 20100501

• Synthesis and biological evaluation of novel pyrazolyl-2,4-thiazolidinediones as anti-inflammatory and neuroprotective agents.

  Bioorganic & medicinal chemistry 20100301

• Lack of association between thiazolidinediones and macular edema in type 2 diabetes: the ACCORD eye substudy.

  Archives of ophthalmology (Chicago, Ill. : 1960) 20100301

• Binding of histidine in the (Cys)3(His)1-coordinated [2Fe-2S] cluster of human mitoNEET.

  Journal of the American Chemical Society 20100217

• Investigation of the role of the thiazolidinedione ring of troglitazone in inducing hepatotoxicity.

  Toxicology letters 20100201

• Discovery of 5-aryloxy-2,4-thiazolidinediones as potent GPR40 agonists.

  Bioorganic & medicinal chemistry letters 20100201

• Structure-based design of a thiazolidinedione which targets the mitochondrial protein mitoNEET.

  Bioorganic & medicinal chemistry letters 20100201

• Thiazolidinedione therapy for nonalcoholic steatohepatitis: go, stop, or proceed with caution?

  Hepatology (Baltimore, Md.) 20100201

• Thiazolidinedione attenuate proteinuria and glomerulosclerosis in Adriamycin-induced nephropathy rats via slit diaphragm protection.

  Nephrology (Carlton, Vic.) 20100201

• Managing highly insulin-resistant diabetes mellitus: weight loss approaches and medical management.

  Postgraduate medicine 20100101

• Biguanide, but not thiazolidinedione, improved insulin resistance in Werner syndrome.

  Journal of the American Geriatrics Society 20100101

• Saxagliptin: a new dipeptidyl peptidase-4 inhibitor for type 2 diabetes.

  Cardiology in review 20100101

• Osteopontin is required for the early onset of high fat diet-induced insulin resistance in mice.

  PloS one 20100101

• Synergistic effect of phytochemicals in combination with hypoglycemic drugs on glucose uptake in myotubes.

  Phytomedicine : international journal of phytotherapy and phytopharmacology 20091201

• Importance of changes in adipose tissue insulin resistance to histological response during thiazolidinedione treatment of patients with nonalcoholic steatohepatitis.

  Hepatology (Baltimore, Md.) 20091001

• Synthesis and in vitro anticancer activity of 2,4-azolidinedione-acetic acids derivatives.

  European journal of medicinal chemistry 20090901

• A comparison between simplified and intensive dose-titration algorithms using AIR inhaled insulin for insulin-naive patients with type 2 diabetes in a randomized noninferiority trial.

  Diabetes technology & therapeutics 20090901

• CoMFA and CoMSIA analysis of 2,4-thiazolidinediones derivatives as aldose reductase inhibitors.

  Journal of molecular modeling 20090701

• A randomized trial of therapies for type 2 diabetes and coronary artery disease.

  The New England journal of medicine 20090611

• Proangiogenic contribution of adiponectin toward mammary tumor growth in vivo.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20090515

• Synthesis, antimicrobial and cytotoxic activities of some 5-arylidene-4-thioxo-thiazolidine-2-ones.

  European journal of medicinal chemistry 20090501

• Synthesis of novel thiourea, thiazolidinedione and thioparabanic acid derivatives of 4-aminoquinoline as potent antimalarials.

  Bioorganic & medicinal chemistry letters 20090501

• Translating science into clinical practice: focus on vildagliptin in combination with metformin.

  Diabetes, obesity & metabolism 20090501

• Thiazolidinedione use and the risk of fractures.

  CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne 20090414

• Thiazolidinedione use and the risk of fractures.

  CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne 20090414

• Thiazolidinedione-induced fluid retention is independent of collecting duct alphaENaC activity.

  Journal of the American Society of Nephrology : JASN 20090401

• Quantitative structure-activity relationship models with receptor-dependent descriptors for predicting peroxisome proliferator-activated receptor activities of thiazolidinedione and oxazolidinedione derivatives.

  Chemical biology & drug design 20090401

• Synthesis and evaluation of novel inhibitors of Pim-1 and Pim-2 protein kinases.

  Journal of medicinal chemistry 20090108

• Impact of peripheral arterial disease in patients with diabetes--results from PROactive (PROactive 11).

  Atherosclerosis 20090101

• Factors associated with results and conclusions of trials of thiazolidinediones.

  PloS one 20090101

• Thiazolidinedione therapy is not associated with increased colonic neoplasia risk in patients with diabetes mellitus.

  Gastroenterology 20081201

• Thiazolidinedione associated volume overload and pulmonary hypertension.

  Therapeutic advances in cardiovascular disease 20081201

• Synthesis and aldose reductase inhibitory activity of some new chromonyl-2,4-thiazolidinediones.

  European journal of medicinal chemistry 20081101

• An assessment of the effect of thiazolidinedione exposure on the risk of myocardial infarction in type 2 diabetic patients.

  Pharmacoepidemiology and drug safety 20081001

• Glycaemic control among patients with type 2 diabetes mellitus in seven European countries: findings from the Real-Life Effectiveness and Care Patterns of Diabetes Management (RECAP-DM) study.

  Diabetes, obesity & metabolism 20080601

• Hypoglycaemic symptoms, treatment satisfaction, adherence and their associations with glycaemic goal in patients with type 2 diabetes mellitus: findings from the Real-Life Effectiveness and Care Patterns of Diabetes Management (RECAP-DM) Study.

  Diabetes, obesity & metabolism 20080601

• Synthesis, induced-fit docking investigations, and in vitro aldose reductase inhibitory activity of non-carboxylic acid containing 2,4-thiazolidinedione derivatives.

  Bioorganic & medicinal chemistry 20080601

• Thiazolidinedione addition reduces the serum retinol-binding protein 4 in type 2 diabetic patients treated with metformin and sulfonylurea.

  Translational research : the journal of laboratory and clinical medicine 20080601

• [Do thiazolidinediones harm skeletal integrity?].

  Clinical calcium 20080501

• [Relationship between lipid and glucose metabolism and bone mineral metabolism : pleiotropic effects of therapeutic agents for diabetes and hyperlipidemia].

  Clinical calcium 20080501

• Differing pharmacological activities of thiazolidinone analogs at the FSH receptor.

  Biochemical and biophysical research communications 20080411

• T2384, a novel antidiabetic agent with unique peroxisome proliferator-activated receptor gamma binding properties.

  The Journal of biological chemistry 20080404

• Effect of gender, dose, and time on 3-(3,5-dichlorophenyl)-2,4-thiazolidinedione (DCPT)-induced hepatotoxicity in Fischer 344 rats.

  Xenobiotica; the fate of foreign compounds in biological systems 20080401

• Electrophilic alpha-thiocyanation of chiral and achiral N-acyl imides. A convenient route to 5-substituted and 5,5-disubstituted 2,4-thiazolidinediones.

  Bioorganic & medicinal chemistry letters 20080315

• Sitagliptin: a novel agent for the management of type 2 diabetes mellitus.

  American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20080315

• Antiproteinuric and anti-inflammatory effects of thiazolidinedione.

  Nephrology (Carlton, Vic.) 20080201

• Oral antidiabetic medication adherence and glycemic control in managed care.

  The American journal of managed care 20080201

• Efficacy and tolerability of vildagliptin vs. pioglitazone when added to metformin: a 24-week, randomized, double-blind study.

  Diabetes, obesity & metabolism 20080101

• Fat and beyond: the diverse biology of PPARgamma.

  Annual review of biochemistry 20080101

• Statins but not thiazolidinediones attenuate albumin-mediated chemokine production by proximal tubular cells independently of endocytosis.

  American journal of nephrology 20080101

• Performing meta-analysis with incomplete statistical information in clinical trials.

  BMC medical research methodology 20080101

• Outcomes of adding second hypoglycemic drug after metformin monotherapy failure among type 2 diabetes in Hungary.

  Health and quality of life outcomes 20080101

• Thiazolidinedione use and post-operative atrial fibrillation: a US nested case-control study.

  Current medical research and opinion 20071101

• Adipose tissue integrity as a prerequisite for systemic energy balance: a critical role for peroxisome proliferator-activated receptor gamma.

  The Journal of biological chemistry 20071012

• Synthesis and three-dimensional qualitative structure selectivity relationship of 3,5-disubstituted-2,4-thiazolidinedione derivatives as COX2 inhibitors.

  Archives of pharmacal research 20071001

• Cytosolic aspartate aminotransferase, a new partner in adipocyte glyceroneogenesis and an atypical target of thiazolidinedione.

  The Journal of biological chemistry 20070810

• Prepartum 2,4-thiazolidinedione alters metabolic dynamics and dry matter intake of dairy cows.

  Journal of dairy science 20070801

• Secondary failure of glycemic control for patients adding thiazolidinedione or sulfonylurea therapy to a metformin regimen.

  The American journal of managed care 20070801

• Pharmacogenetics of thiazolidinedione therapy.

  Pharmacogenomics 20070801

• Heregulin-mediated ErbB2-ERK signaling activates hyaluronan synthases leading to CD44-dependent ovarian tumor cell growth and migration.

  The Journal of biological chemistry 20070706

• The impact of thiazolidinedione use on outcomes in ambulatory patients with diabetes mellitus and heart failure.

  Journal of the American College of Cardiology 20070703

• Effect of thiazolidinedione therapy on restenosis after coronary stent implantation: a meta-analysis of randomized controlled trials.

  American heart journal 20070701

• Mechanism of thiazolidinedione-dependent cell death in Jurkat T cells.

  Molecular pharmacology 20070601

• Thiazolidinedione treatment decreases bone mineral density in type 2 diabetic men.

  Diabetes care 20070601

• Pioglitazone and rosiglitazone decrease prostaglandin E2 in non-small-cell lung cancer cells by up-regulating 15-hydroxyprostaglandin dehydrogenase.

  Molecular pharmacology 20070601

• Thiazolidinedione therapy gets complicated: is bone loss the price of improved insulin resistance?

  Diabetes care 20070601

• Inhaled insulin for diabetes mellitus.

  The New England journal of medicine 20070517

• Novel thyroid hormone receptor antagonists with an N-alkylated diphenylamine skeleton.

  Bioorganic & medicinal chemistry 20070501

• Hepatocyte growth factor induces glucose uptake in 3T3-L1 adipocytes through A Gab1/phosphatidylinositol 3-kinase/Glut4 pathway.

  The Journal of biological chemistry 20070406

• Summaries for patients. Exenatide therapy for type 2 diabetes.

  Annals of internal medicine 20070403

• The effect of adding exenatide to a thiazolidinedione in suboptimally controlled type 2 diabetes: a randomized trial.

  Annals of internal medicine 20070403

• Exenatide in combination therapy: small study, big market, and many unanswered questions.

  Annals of internal medicine 20070403

• Thiazolidinedione ameliorates renal injury in experimental diabetic rats through anti-inflammatory effects mediated by inhibition of NF-kappaB activation.

  American journal of physiology. Renal physiology 20070401

• Vildagliptin in combination with pioglitazone improves glycaemic control in patients with type 2 diabetes failing thiazolidinedione monotherapy: a randomized, placebo-controlled study.

  Diabetes, obesity & metabolism 20070301

• Beta-cell ABCA1 influences insulin secretion, glucose homeostasis and response to thiazolidinedione treatment.

  Nature medicine 20070301

• Human visfatin expression: relationship to insulin sensitivity, intramyocellular lipids, and inflammation.

  The Journal of clinical endocrinology and metabolism 20070201

• The ASP receptor C5L2 is regulated by metabolic hormones associated with insulin resistance.

  Biochemistry and cell biology = Biochimie et biologie cellulaire 20070201

• Effect of thiazolidinedione on the proliferation of bovine retinal endothelial cells stimulated by vascular endothelial cell growth factor.

  Japanese journal of ophthalmology 20070101

• Thiazolidinedione induced thyroid associated orbitopathy.

  BMC ophthalmology 20070101

• The lipogenic enzymes DGAT1, FAS, and LPL in adipose tissue: effects of obesity, insulin resistance, and TZD treatment.

  Journal of lipid research 20061101

• Surface-specific effects of a PPARgamma agonist, darglitazone, on bone in mice.

  Bone 20061001

• Thiazolidinedione use and bone loss in older diabetic adults.

  The Journal of clinical endocrinology and metabolism 20060901

• Plasma concentrations of vascular endothelial growth factor are associated with peripheral oedema in patients treated with thiazolidinedione.

  Diabetologia 20060901

• Endothelial dysfunction and its role in diabetic vascular disease.

  Endocrinology and metabolism clinics of North America 20060901

• Thailand diabetes registry project: glycemic control in Thai type 2 diabetes and its relation to hypoglycemic agent usage.

  Journal of the Medical Association of Thailand = Chotmaihet thangphaet 20060801

• Amelioration of age-related inflammation and oxidative stress by PPARgamma activator: suppression of NF-kappaB by 2,4-thiazolidinedione.

  Experimental gerontology 20060601

• Can thiazolidinediones delay disease progression in type 2 diabetes?

  Current medical research and opinion 20060601

• Etiology of insulin resistance.

  The American journal of medicine 20060501

• Insulin sensitizing pharmacotherapy for prevention of myocardial infarction in patients with diabetes mellitus.

  The American journal of cardiology 20060301

• Outcomes associated with introduction of thiazolidinedione therapy in Medicaid enrolled patients with type 2 diabetes: an updated and expanded retrospective analysis.

  Current medical research and opinion 20060301

• Quantitative structure-activity analysis of 5-arylidene-2,4-thiazolidinediones as aldose reductase inhibitors.

  Bioorganic & medicinal chemistry letters 20060201

• Attenuation of experimental colonic injury by thiazolidinedione agents.

  Inflammation research : official journal of the European Histamine Research Society ... [et al.] 20060101

• Treatment of type 2 diabetes. Use of fixed-dose oral combinations.

  Postgraduate medicine 20060101

• Synthesis and antidiabetic activity of novel 2,4-thiazolidinedione derivatives containing a thiazole ring.

  Arzneimittel-Forschung 20060101

• Oral agents in managing diabetes mellitus in children and adolescents.

  Pediatric clinics of North America 20051201

• SAR and 3D-QSAR studies on thiadiazolidinone derivatives: exploration of structural requirements for glycogen synthase kinase 3 inhibitors.

  Journal of medicinal chemistry 20051117

• [Insulin resistance: the adipose tissue in the focus].

  Orvosi hetilap 20051023

• [The effects of thiazolidinedione from the cardiologic viewpoint].

  Medizinische Monatsschrift fur Pharmazeuten 20051001

• Impact of thiazolidinedione therapy on atherogenesis.

  Current atherosclerosis reports 20050901

• Thiazolidinedione treatment inhibits bile duct proliferation and fibrosis in a rat model of chronic cholestasis.

  World journal of gastroenterology 20050828

• Peroxisome proliferator-activated receptor gamma ligands induce cell cycle arrest and apoptosis in human renal carcinoma cell lines.

  Acta pharmacologica Sinica 20050601

• The nonthiazolidinedione tyrosine-based peroxisome proliferator-activated receptor gamma ligand GW7845 induces apoptosis and limits migration and invasion of rat and human glioma cells.

  The Journal of pharmacology and experimental therapeutics 20050501

• Dietary (n-3) polyunsaturated fatty acids inhibit HER-2/neu-induced breast cancer in mice independently of the PPARgamma ligand rosiglitazone.

  The Journal of nutrition 20050501

• [Polycystic ovary syndrome].

  Nihon rinsho. Japanese journal of clinical medicine 20050401

• Thiazolidinedione treatment attenuates diffuse neointimal hyperplasia in restenotic lesions after coronary stent implantation in type 2 diabetic patients: an intravascular ultrasound study.

  Journal of cardiology 20050401

• Peroxisome proliferator-activated receptor gamma-independent activation of p38 MAPK by thiazolidinediones involves calcium/calmodulin-dependent protein kinase II and protein kinase R: correlation with endoplasmic reticulum stress.

  The Journal of biological chemistry 20050318

• PPAR-gamma activation fails to provide myocardial protection in ischemia and reperfusion in pigs.

  American journal of physiology. Heart and circulatory physiology 20050301

• Peroxisome proliferator-activated receptor gamma agonists promote TRAIL-induced apoptosis by reducing survivin levels via cyclin D3 repression and cell cycle arrest.

  The Journal of biological chemistry 20050225

• Corepressors selectively control the transcriptional activity of PPARgamma in adipocytes.

  Genes & development 20050215

• [Selection of oral antidiabetic drugs].

  Nihon rinsho. Japanese journal of clinical medicine 20050201

• The utility of oral diabetes medications in type 2 diabetes of the young.

  Current diabetes reviews 20050201

• Peroxisome proliferation-activated receptor (PPAR)gamma is not necessary for synthetic PPARgamma agonist inhibition of inducible nitric-oxide synthase and nitric oxide.

  The Journal of pharmacology and experimental therapeutics 20050101

• Potential role of oral thiazolidinedione therapy in preserving beta-cell function in type 2 diabetes mellitus.

  Drugs 20050101

• Efficacy and safety of ezetimibe co-administered with simvastatin in thiazolidinedione-treated type 2 diabetic patients.

  Diabetes, obesity & metabolism 20050101

• Thiazolidinediones improve insulin sensitivity in adipose tissue and reduce the hyperlipidaemia without affecting the hyperglycaemia in a transgenic model of type 2 diabetes.

  Diabetologia 20041201

• Thiazolidinediones: a review of their mechanisms of insulin sensitization, therapeutic potential, clinical efficacy, and tolerability.

  Diabetes technology & therapeutics 20041201

• Variance-modeled posterior inference of microarray data: detecting gene-expression changes in 3T3-L1 adipocytes.

  Bioinformatics (Oxford, England) 20041122

• Peroxisome proliferator-activated receptor gamma-dependent and -independent growth inhibition of gastrointestinal tumour cells.

  Genes to cells : devoted to molecular & cellular mechanisms 20041101

• Evidence for a new human CYP1A1 regulation pathway involving PPAR-alpha and 2 PPRE sites.

  Gastroenterology 20041101

• Synthesis and biological activity of benzoxazole containing thiazolidinedione derivatives.

  Archives of pharmacal research 20041101

• Application of liquid chromatography/mass spectrometry and nuclear magnetic resonance to the identification of degradates of a novel insulin sensitizer in aqueous solutions.

  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20041025

• Integrated genomic and proteomic analyses of gene expression in Mammalian cells.

  Molecular & cellular proteomics : MCP 20041001

• Healthcare costs and prescription adherence with introduction of thiazolidinedione therapy in Medicaid type 2 diabetic patients: a retrospective data analysis.

  Current medical research and opinion 20041001

• Thiazolidinedione, a peroxisome proliferator-activated receptor-gamma ligand, inhibits growth and metastasis of HT-29 human colon cancer cells through differentiation-promoting effects.

  International journal of oncology 20040901

• Retinoid X receptor-gamma and peroxisome proliferator-activated receptor-gamma expression predicts thyroid carcinoma cell response to retinoid and thiazolidinedione treatment.

  Molecular cancer therapeutics 20040801

• Continuation of thiazolidinedione therapy in patients without left ventricular dysfunction who developed edema and congestive-heart-failure symptoms.

  American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20040801

• Limited tumor growth (HT29) in vivo under RO205-2349 is due to increased apoptosis and reduced cell volume but not to decreased proliferation rate.

  Cancer letters 20040708

• Peroxisome proliferator activated receptors alpha and gamma require zinc for their anti-inflammatory properties in porcine vascular endothelial cells.

  The Journal of nutrition 20040701

• Increased adipose tissue expression of Grb14 in several models of insulin resistance.

  FASEB journal : official publication of the Federation of American Societies for Experimental Biology 20040601

• Quantitative determination of a novel insulin sensitizer and its para-hydroxylated metabolite in human plasma by LC-MS/MS.

  Journal of pharmaceutical and biomedical analysis 20040528

• Transactivation of the PPAR-responsive enhancer module in chemopreventive glutathione S-transferase gene by the peroxisome proliferator-activated receptor-gamma and retinoid X receptor heterodimer.

  Cancer research 20040515

• Coronary vasomotor abnormalities in insulin-resistant individuals.

  Annals of internal medicine 20040504

• Interaction of tumor necrosis factor-alpha- and thiazolidinedione-regulated pathways in obesity.

  Endocrinology 20040501

• Thiazolidinedione-induced congestive heart failure.

  The Annals of pharmacotherapy 20040501

• Thiazolidinediones reduce the LDL binding affinity of non-human primate vascular cell proteoglycans.

  Diabetologia 20040501

• Synthesis and biological activity of novel substituted pyridines and purines containing 2,4-thiazolidinedione.

  European journal of medicinal chemistry 20040501

• Cinnamic acid based thiazolidinediones inhibit human P450c17 and 3beta-hydroxysteroid dehydrogenase and improve insulin sensitivity independent of PPARgamma agonist activity.

  Journal of molecular endocrinology 20040401

• [Achieving better control of blood sugar--understanding of oral hypoglycemic agents according to their characteristics in pharmacological action mechanism (discussion)].

  Nihon rinsho. Japanese journal of clinical medicine 20040401

• Complex distribution, not absolute amount of adiponectin, correlates with thiazolidinedione-mediated improvement in insulin sensitivity.

  The Journal of biological chemistry 20040326

• Type 2 diabetes mellitus: what is the optimal treatment regimen?

  The American journal of medicine 20040308

• Increased CD36 protein as a response to defective insulin signaling in macrophages.

  The Journal of clinical investigation 20040301

• Prevalence of edema in patients receiving combination therapy with insulin and thiazolidinedione.

  American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20040215

• Antiproliferative effect of fluvastatin and thiazolidinedione in mesangial cells of diabetic rats.

  Pediatric nephrology (Berlin, Germany) 20040101

• Antitumor effects of peroxisome proliferator activate receptor gamma ligands on anaplastic thyroid carcinoma.

  International journal of oncology 20040101

• Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association.

  Diabetes care 20040101

• Cardiovascular implications of thiazolidinedione therapy.

  Progress in cardiovascular nursing 20040101

• Cbl PYXXM motifs activate the P85 subunit of phosphatidylinositol 3-kinase, Crk, atypical protein kinase C, and glucose transport during thiazolidinedione action in 3T3/L1 and human adipocytes.

  Biochemistry 20031209

• The roles of insulin resistance, hyperinsulinemia, and thiazolidinediones in cardiovascular disease.

  The American journal of medicine 20031208

• Beta-cell rejuvenation with thiazolidinediones.

  The American journal of medicine 20031208

• Free fatty acids and type 2 diabetes mellitus.

  The American journal of medicine 20031208

• Hypertension and nephropathy.

  The American journal of medicine 20031208

• The vascular biology of atherosclerosis.

  The American journal of medicine 20031208

• Novel actions of thiazolidinediones on vascular function and exercise capacity.

  The American journal of medicine 20031208

• Insulin resistance and the effects of thiazolidinediones on cardiac metabolism.

  The American journal of medicine 20031208

• Vascular reactivity and thiazolidinediones.

  The American journal of medicine 20031208

• Thiazolidinedione regulation of smooth muscle cell proliferation.

  The American journal of medicine 20031208

• Considerations for management of fluid dynamic issues associated with thiazolidinediones.

  The American journal of medicine 20031208

• Muscle-specific Pparg deletion causes insulin resistance.

  Nature medicine 20031201

• Antiedematogenic activity of two thiazolidine derivatives: N-tryptophyl-5-(3,5-di-tert-butyl-4-hydroxybenzylidene) rhodanine (GS26) and N-tryptophyl-5-(3,5-di-tert-butyl-4-hydroxybenzylidene)-2,4-thiazolidinedione (GS28).

  Chemical & pharmaceutical bulletin 20031201

• [The effect of peroxisome proliferator-activated receptor alpha and gamma ligands on free fatty acid-induced INS-1 cell impairment].

  Zhonghua nei ke za zhi 20031201

• Regulation of glyceroneogenesis and phosphoenolpyruvate carboxykinase by fatty acids, retinoic acids and thiazolidinediones: potential relevance to type 2 diabetes.

  Biochimie 20031201

• Central role of the adipocyte in the insulin-sensitising and cardiovascular risk modifying actions of the thiazolidinediones.

  Biochimie 20031201

• Paradoxical lowering of high-density lipoprotein cholesterol level in 2 patients receiving fenofibrate and a thiazolidinedione.

  Annals of internal medicine 20031104

• Zinc modulates PPARgamma signaling and activation of porcine endothelial cells.

  The Journal of nutrition 20031001

• A PPAR agonist improves TNF-alpha-induced insulin resistance of adipose tissue in mice.

  Biochemical and biophysical research communications 20030919

• Adiponectin gene activation by thiazolidinediones requires PPAR gamma 2, but not C/EBP alpha-evidence for differential regulation of the aP2 and adiponectin genes.

  Biochemical and biophysical research communications 20030905

• Thiazolidinedione-associated congestive heart failure and pulmonary edema.

  Mayo Clinic proceedings 20030901

• Diabetes drugs a problem in heart failure.

  Harvard heart letter : from Harvard Medical School 20030901

• Abietic acid activates peroxisome proliferator-activated receptor-gamma (PPARgamma) in RAW264.7 macrophages and 3T3-L1 adipocytes to regulate gene expression involved in inflammation and lipid metabolism.

  FEBS letters 20030828

• Lipoprotein distribution in the metabolic syndrome, type 2 diabetes mellitus, and familial combined hyperlipidemia.

  The American journal of cardiology 20030818

• Peroxisome proliferator-activated receptor-gamma represses GLUT4 promoter activity in primary adipocytes, and rosiglitazone alleviates this effect.

  The Journal of biological chemistry 20030815

• Muscle-specific PPARgamma-deficient mice develop increased adiposity and insulin resistance but respond to thiazolidinediones.

  The Journal of clinical investigation 20030815

• Synthesis and in vitro evaluation of novel small molecule inhibitors of bacterial arylamine N-acetyltransferases (NATs).

  Bioorganic & medicinal chemistry letters 20030804

• PAT5A: a partial agonist of peroxisome proliferator-activated receptor gamma is a potent antidiabetic thiazolidinedione yet weakly adipogenic.

  The Journal of pharmacology and experimental therapeutics 20030801

• Peroxisome proliferator-activated receptors (PPARS): regulators of gene expression in heart and skeletal muscle.

  Acta physiologica Scandinavica 20030801

• Benefits of combination therapy of insulin and oral hypoglycemic agents.

  Archives of internal medicine 20030801

• Metformin and thiazolidinedione use in Medicare patients with heart failure.

  JAMA 20030702

• [Insulin-sensitizing agents: metformin and thiazolidinedione derivatives].

  Nihon rinsho. Japanese journal of clinical medicine 20030701

• New developments in type 2 diabetes mellitus: combination therapy with a thiazolidinedione.

  Clinical therapeutics 20030701

• The metabolic syndrome: peroxisome proliferator-activated receptor gamma and its therapeutic modulation.

  The Journal of clinical endocrinology and metabolism 20030601

• 5-Aryl thiazolidine-2,4-diones as selective PPARgamma agonists.

  Bioorganic & medicinal chemistry letters 20030519

• Modulation of PPARgamma activity with pharmaceutical agents: treatment of insulin resistance and atherosclerosis.

  Journal of cellular biochemistry 20030501

• PPAR-gamma receptor ligands: novel therapy for pituitary adenomas.

  The Journal of clinical investigation 20030501

• Identification of novel metabolites of pioglitazone in rat and dog.

  Xenobiotica; the fate of foreign compounds in biological systems 20030501

• Lessons learned from landmark trials of type 2 diabetes mellitus and potential applications to clinical practice.

  Postgraduate medicine 20030501

• Insulin resistance syndrome. Description, pathogenesis, and management.

  Postgraduate medicine 20030501

• Constructing an algorithm for managing type 2 diabetes. Focus on role of the thiazolidinediones.

  Postgraduate medicine 20030501

• A non-thiazolidinedione partial peroxisome proliferator-activated receptor gamma ligand inhibits vascular smooth muscle cell growth.

  European journal of pharmacology 20030418

• Fluid retention after initiation of thiazolidinedione therapy in diabetic patients with established chronic heart failure.

  Journal of the American College of Cardiology 20030416

• Comparative effects of thiazolidinediones on in vitro P450 enzyme induction and inhibition.

  Drug metabolism and disposition: the biological fate of chemicals 20030401

• Do peroxisome proliferation receptor-gamma antagonists have clinical potential as combined antiobesity and antidiabetic drugs?

  Expert opinion on investigational drugs 20030401

• Insulin sensitizers.

  Mayo Clinic proceedings 20030401

• Resistin: molecular history and prognosis.

  Journal of molecular medicine (Berlin, Germany) 20030401

• Synthesis and antihyperglycemic activity of erythrose, ribose and substituted pyrrolidine containing thiazolidinedione derivatives.

  Chemical & pharmaceutical bulletin 20030301

• Peroxisome proliferator-activated receptor gamma thiazolidinedione agonists increase glucose metabolism in astrocytes.

  The Journal of biological chemistry 20030221

• A human cell surface receptor activated by free fatty acids and thiazolidinedione drugs.

  Biochemical and biophysical research communications 20030207

• Studies on non-thiazolidinedione antidiabetic agents. 2. Novel oxyiminoalkanoic acid derivatives as potent glucose and lipid lowering agents.

  Chemical & pharmaceutical bulletin 20030201

• PPARgamma agonists in the treatment of type II diabetes: is increased fatness commensurate with long-term efficacy?

  International journal of obesity and related metabolic disorders : journal of the International Association for the Study of Obesity 20030201

• Treatment of insulin resistance in uremia.

  The International journal of artificial organs 20030201

• Activation of PPARgamma increases PTEN expression in pancreatic cancer cells.

  Biochemical and biophysical research communications 20030131

• Development of insulin resistance and reversal by thiazolidinediones in C2C12 skeletal muscle cells.

  Biochemical pharmacology 20030115

• Vanadyl-thiazolidinedione combination agents for diabetes therapy.

  Bioconjugate chemistry 20030101

• Synthesis and hypoglycemic activity of some substituted flavonyl thiazolidinedione derivatives--fifth communication: flavonyl benzyl substituted 2,4-thiazolidinediones.

  Farmaco (Societa chimica italiana : 1989) 20030101

• Continuing education.

  Diabetic medicine : a journal of the British Diabetic Association 20030101

• [Lipodystrophies: what treatment?].

  Journees annuelles de diabetologie de l'Hotel-Dieu 20030101

• Why I initiate therapy with two insulin sensitizers in patients with type 2 diabetes.

  Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists 20030101

• Thiazolidinedione therapy: the benefits of aggressive and early use in type 2 diabetes.

  Diabetes technology & therapeutics 20030101

• Pancreatic beta-cell loss and preservation in type 2 diabetes.

  Clinical therapeutics 20030101

• Thiazolidinediones, peripheral edema, and type 2 diabetes: incidence, pathophysiology, and clinical implications.

  Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists 20030101

• Therapy for type 2 diabetes.

  Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists 20030101

• Brown adipocytes are novel sites of expression and regulation of adiponectin and resistin.

  FEBS letters 20021218

• 15-PGJ2, but not thiazolidinediones, inhibits cell growth, induces apoptosis, and causes downregulation of Stat3 in human oral SCCa cells.

  British journal of cancer 20021202

• Prior thiazolidinedione treatment preserves insulin sensitivity in normal rats during acute fatty acid elevation: role of the liver.

  Endocrinology 20021201

• [Thiazolidinediones in type 2 diabetes. Role of peroxisome proliferator-activated receptor gamma (PPARgamma)].

  Annales d'endocrinologie 20021201

• A truly deadly quartet: obesity, hypertension, hypertriglyceridemia, and hyperinsulinemia.

  Cleveland Clinic journal of medicine 20021201

• Effective use of thiazolidinediones for the treatment of glucocorticoid-induced diabetes.

  Diabetes research and clinical practice 20021101

• Insulin resistance, diabetes, and atherosclerosis: thiazolidinediones as therapeutic interventions.

  Current cardiology reports 20021101

• Therapeutic options for the management of type 2 diabetes mellitus.

  The American journal of managed care 20021101

• [Discovery and development of a new insulin sensitizing agent, pioglitazone].

  Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan 20021101

• Oral anti diabetic polychemotherapy in type 2 diabetes mellitus.

  Diabetes & metabolism 20021101

• The effect of thiazolidinediones on plasma adiponectin levels in normal, obese, and type 2 diabetic subjects.

  Diabetes 20021001

• Biochemical correlates of thiazolidinedione-induced adipocyte differentiation by high-resolution magic angle spinning NMR spectroscopy.

  Magnetic resonance in medicine 20021001

• Seeking sweet relief for diabetes.

  Nature biotechnology 20021001

• A futile metabolic cycle activated in adipocytes by antidiabetic agents.

  Nature medicine 20021001

• PPARgamma ligands inhibit primary tumor growth and metastasis by inhibiting angiogenesis.

  The Journal of clinical investigation 20021001

• Studies on non-thiazolidinedione antidiabetic agents. 1. Discovery of novel oxyiminoacetic acid derivatives.

  Chemical & pharmaceutical bulletin 20021001

• Effects of thiazolidinediones for early treatment of type 2 diabetes mellitus.

  The American journal of managed care 20021001

• Thiazolidinediones in the treatment of managed care patients with type 2 diabetes.

  The American journal of managed care 20021001

• [Combination therapy with biguanides].

  Nihon rinsho. Japanese journal of clinical medicine 20021001

• Experimental approaches to study PPAR gamma agonists as antidiabetic drugs.

  Methods and findings in experimental and clinical pharmacology 20021001

• Thiazolidinediones increase the number of platelets in immune thrombocytopenic purpura mice via inhibition of phagocytic activity of the reticulo-endothelial system.

  Life sciences 20020913

• PMT13, a pyrimidone analogue of thiazolidinedione improves insulin resistance-associated disorders in animal models of type 2 diabetes.

  Diabetes, obesity & metabolism 20020901

• Combination therapy with nateglinide and a thiazolidinedione improves glycemic control in type 2 diabetes.

  Diabetes care 20020901

• Thiazolidinediones: metabolic actions in vitro.

  Diabetologia 20020901

• [Mechanisms of thiazolidinedione derivatives for hypoglycemic and insulin sensitizing effects].

  Nihon rinsho. Japanese journal of clinical medicine 20020901

• [Glitazone--a new drug for type 2 diabetes].

  Nihon rinsho. Japanese journal of clinical medicine 20020901

• [Combination therapy of insulin sensitizer, thiazolidinedione drugs, and sulfonylurea].

  Nihon rinsho. Japanese journal of clinical medicine 20020901

• [Chemical structures and pharmacological characteristics of novel non-thiazolidinedione insulin sensitizer (JTT-501, FK614)].

  Nihon rinsho. Japanese journal of clinical medicine 20020901

• Thiazolidinedione activation of peroxisome proliferator-activated receptor gamma can enhance mitochondrial potential and promote cell survival.

  The Journal of biological chemistry 20020830

• Synthesis and biological activity of novel pyrimidinone containing thiazolidinedione derivatives.

  Bioorganic & medicinal chemistry 20020801

• Possible vascular-protective effects of antidiabetic agents such as the thiazolidinediones (TZDs).

  Clinical therapeutics 20020801

• Biology and toxicology of PPARgamma ligands.

  Human & experimental toxicology 20020801

• Endothelium, inflammation, and diabetes.

  Current diabetes reports 20020801

• The gene encoding the Acyl-CoA-binding protein is activated by peroxisome proliferator-activated receptor gamma through an intronic response element functionally conserved between humans and rodents.

  The Journal of biological chemistry 20020726

• Thiazolidinedione, a peroxisome proliferator-activated receptor-gamma ligand, modulates the E-cadherin/beta-catenin system in a human pancreatic cancer cell line, BxPC-3.

  International journal of oncology 20020701

• Impaired ('diabetic') insulin signaling and action occur in fat cells long before glucose intolerance--is insulin resistance initiated in the adipose tissue?

  International journal of obesity and related metabolic disorders : journal of the International Association for the Study of Obesity 20020701

• Role of peroxisome proliferator-activated receptor-gamma in maintenance of the characteristics of mature 3T3-L1 adipocytes.

  Diabetes 20020701

• Combination of insulin and thiazolidinedione therapy in massively obese patients with Type 2 diabetes.

  Diabetic medicine : a journal of the British Diabetic Association 20020701

• Peroxisome proliferator-activated receptor-gamma expression in lung.

  Chest 20020701

• Thiazolidinedione-induced edema.

  Pharmacotherapy 20020701

• Understanding insulin-resistance in type 2 diabetes.

  Journal of the National Medical Association 20020701

• Risk of adverse events with concomitant use of atorvastatin or simvastatin and glucose-lowering drugs (thiazolidinediones, metformin, sulfonylurea, insulin, and acarbose).

  The American journal of cardiology 20020601

• Genetics and molecular biology: peroxisome proliferator-activated receptor gamma still full of surprises.

  Current opinion in lipidology 20020601

• The glitazones: a new treatment for type 2 diabetes mellitus.

  Intensive & critical care nursing 20020601

• Peroxisome proliferator-activated receptor (PPAR) gamma coactivator-1 recruitment regulates PPAR subtype specificity.

  The Journal of biological chemistry 20020510

• Thiazolidinediones in the treatment of type 2 diabetes.

  Expert opinion on pharmacotherapy 20020501

• Clinical inquiries. How beneficial are thiazolidinediones for diabetes mellitus?

  The Journal of family practice 20020501

• Synthesis and aldose reductase inhibitory activity of 5-arylidene-2,4-thiazolidinediones.

  Bioorganic & medicinal chemistry 20020401

• Thiazolidinedione treatment normalizes insulin resistance and ischemic injury in the zucker Fatty rat heart.

  Diabetes 20020401

• 15-Deoxy-Delta12,14-prostaglandin J2 regulates mesangial cell proliferation and death.

  Kidney international 20020401

• Polycystic ovary syndrome. Long term sequelae and management.

  Minerva ginecologica 20020401

• [PPARgamma and insulin resistance].

  Annales d'endocrinologie 20020401

• [Glitazones and weight gain].

  Annales d'endocrinologie 20020401

• [Precautions for use and contraindications of thiazolidinediones. A cardiologist opinion].

  Annales d'endocrinologie 20020401

• [Is a new therapeutic class justified in the treatment of type 2 diabetes?].

  Annales d'endocrinologie 20020401

• Novel 5-substituted 2,4-thiazolidinedione and 2,4-oxazolidinedione derivatives as insulin sensitizers with antidiabetic activities.

  Journal of medicinal chemistry 20020328

• Activation of peroxisome proliferator-activated receptor-gamma stimulates the growth arrest and DNA-damage inducible 153 gene in non-small cell lung carcinoma cells.

  Oncogene 20020328

• Thiazolidinedione derivatives as novel therapeutic agents to prevent the development of chronic pancreatitis.

  Pancreas 20020301

• Regional differences in the response of human pre-adipocytes to PPARgamma and RXRalpha agonists.

  Diabetes 20020301

• Type 2 diabetes therapy. A pathophysiologically based approach.

  Postgraduate medicine 20020301

• Toxicological consequences of altered peroxisome proliferator-activated receptor gamma (PPARgamma) expression in the liver: insights from models of obesity and type 2 diabetes.

  Biochemical pharmacology 20020101

• Treatment of type 2 diabetes mellitus: pharmacologic intervention.

  The Journal of cardiovascular nursing 20020101

• Diabetes mellitus. Medication update.

  Southern medical journal 20020101

• A treatment for Mr WP: thiazolidinediones after troglitazone.

  Diabetic medicine : a journal of the British Diabetic Association 20020101

• Clinical evidence of thiazolidinedione-induced improvement of pancreatic beta-cell function in patients with type 2 diabetes mellitus.

  Diabetes, obesity & metabolism 20020101

• Type 2 diabetes management: a comprehensive clinical review of oral medications.

  Comprehensive therapy 20020101

• The mode of action of thiazolidinediones.

  Diabetes/metabolism research and reviews 20020101

• Differentiating members of the thiazolidinedione class: a focus on efficacy.

  Diabetes/metabolism research and reviews 20020101

• Differentiating members of the thiazolidinedione class: a focus on safety.

  Diabetes/metabolism research and reviews 20020101

• Where thiazolidinediones will fit.

  Diabetes/metabolism research and reviews 20020101

• Novel insulin sensitizers: pharmacogenomic aspects.

  Pharmacogenomics 20020101

• Thiazolidinediones for the prevention of diabetes in the non-obese diabetic (NOD) mouse: implications for human type 1 diabetes.

  Diabetes/metabolism research and reviews 20020101

• PPAR(gamma) and glucose homeostasis.

  Annual review of nutrition 20020101

• Does hypertriglyceridemia present an indication for pioglitazone therapy in diabetes?

  Diabetes technology & therapeutics 20020101

• Metabolic and additional vascular effects of thiazolidinediones.

  Drugs 20020101

• [Changes in carbohydrate metabolism in the HIV/AIDS patient].

  Nutricion hospitalaria 20020101

• Glitazones: clinical effects and molecular mechanisms.

  Annals of medicine 20020101

• Long-term efficacy of triple oral therapy for type 2 diabetes mellitus.

  Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists 20020101

• Thiazolidinedione therapy in a patient with diabetes after cardiac transplantation.

  Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists 20020101

• Oral combination therapy for type 2 diabetes.

  Diabetes/metabolism research and reviews 20020101

• Oral bioavailability and pharmacokinetics of PAT-5A, a new insulin sensitizer in rats.

  European journal of drug metabolism and pharmacokinetics 20020101

• Insulin-sensitizing agents--thiazolidinediones (glitazones).

  Current medical research and opinion 20020101

• Differences in lipid profiles of patients given rosiglitazone followed by pioglitazone.

  Current medical research and opinion 20020101

• Plasma resistin levels in patients with type 1 and type 2 diabetes mellitus and in healthy controls.

  Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme 20020101

• Enhancement of the aquaporin adipose gene expression by a peroxisome proliferator-activated receptor gamma.

  The Journal of biological chemistry 20011221

• [Insulin sensitizer drugs, thiazolidinediones: current state and prospect].

  Nihon rinsho. Japanese journal of clinical medicine 20011101

• [A role of the PPAR gamma activation in insulin resistance].

  Nihon rinsho. Japanese journal of clinical medicine 20011101

• [Development of new antidiabetic drugs through the advanced knowledge of molecular biology in insulin signal transduction].

  Nihon rinsho. Japanese journal of clinical medicine 20011101

• [Clinical difference between thiazolidinediones and biguanides].

  Nihon rinsho. Japanese journal of clinical medicine 20011101

• [Evaluation of thiazolidinedione derivative drugs for safety].

  Nihon rinsho. Japanese journal of clinical medicine 20011101

• [Clinical usefulness of combination treatment with thiazolidinedione and insulin].

  Nihon rinsho. Japanese journal of clinical medicine 20011101

• PPARgamma agonists inhibit cell growth and suppress the expression of cyclin D1 and EGF-like growth factors in ras-transformed rat intestinal epithelial cells.

  International journal of cancer 20011101

• [Type 2 diabetes. Regulating insulin according to need].

  MMW Fortschritte der Medizin 20011018

• Inhibition of monocyte chemoattractant protein-1 expression in cytokine-treated human lung epithelial cells by thiazolidinedione.

  Chest 20011001

• Stimulated release of arachidonic acid by agonists of the peroxisome proliferator-activated receptor and retinoic acid receptors.

  Prostaglandins, leukotrienes, and essential fatty acids 20011001

• A single element in the phosphoenolpyruvate carboxykinase gene mediates thiazolidinedione action specifically in adipocytes.

  Biochimie 20011001

• Combination oral agent and insulin therapy for type 2 diabetes mellitus.

  Current diabetes reports 20011001

• TNFalpha inhibits insulin's antiapoptotic signaling in vascular smooth muscle cells.

  Biochemical and biophysical research communications 20010928

• Expression of peroxisome proliferator-activated receptor gamma in renal cell carcinoma and growth inhibition by its agonists.

  Biochemical and biophysical research communications 20010928

• Galectin-12, an Adipose-expressed Galectin-like Molecule Possessing Apoptosis-inducing Activity.

  The Journal of biological chemistry 20010907

• Peroxisome proliferator-activated receptor-gamma-independent inhibition of macrophage activation by the non-thiazolidinedione agonist L-796,449. Comparison with the effects of 15-deoxy-delta(12,14)-prostaglandin J(2).

  The Journal of biological chemistry 20010907

• [News in oral antidiabetic therapy].

  Vnitrni lekarstvi 20010901

• Anticancer effects of thiazolidinediones are independent of peroxisome proliferator-activated receptor gamma and mediated by inhibition of translation initiation.

  Cancer research 20010815

• [The thiazolidinedione derivates: a new class of oral blood glucose lowering agents].

  Nederlands tijdschrift voor geneeskunde 20010811

• The adipocyte-secreted protein Acrp30 enhances hepatic insulin action.

  Nature medicine 20010801

• Mechanisms involved in tumor necrosis factor-alpha induction of insulin resistance and its reversal by thiazolidinedione(s).

  The American journal of the medical sciences 20010801

• Pharmacological treatment of insulin resistance in obesity.

  Nutrition, metabolism, and cardiovascular diseases : NMCD 20010801

• [Thiazolidinediones--a new class of oral antidiabetic drugs].

  Orvosi hetilap 20010722

• Expression and characterization of recombinant rat Acyl-CoA synthetases 1, 4, and 5. Selective inhibition by triacsin C and thiazolidinediones.

  The Journal of biological chemistry 20010706

• A new era in type 2 diabetes mellitus treatment?

  The American journal of medicine 20010701

• Insulin resistance induced in dairy steers by tumor necrosis factor alpha is partially reversed by 2,4-thiazolidinedione.

  Domestic animal endocrinology 20010701

• Comparative actions of insulin sensitizers on ion channels in vascular smooth muscle.

  European journal of pharmacology 20010629

• Stage-specific effects of a thiazolidinedione on proliferation, differentiation and PPARgamma mRNA expression in 3T3-L1 adipocytes.

  European journal of pharmacology 20010622

• Type 2 diabetes. How new insights, new drugs are changing clinical practice.

  Geriatrics 20010601

• [Value of glitazones in therapy of type 2 diabetes: pro].

  Deutsche medizinische Wochenschrift (1946) 20010518

• Troglitazone induces GLUT4 translocation in L6 myotubes.

  Diabetes 20010501

• Induction of plasminogen activator inhibitor 1 gene expression in adipocytes by thiazolidinediones.

  FASEB journal : official publication of the Federation of American Societies for Experimental Biology 20010501

• Oral agents in the management of type 2 diabetes mellitus.

  American family physician 20010501

• [Current and future aspects of oral antidiabetic agents in type 2 diabetes].

  Vnitrni lekarstvi 20010501

• New oxadiazolidinedione derivatives as potent and selective human beta3 agonists.

  Bioorganic & medicinal chemistry letters 20010423

• Peroxisome proliferator-activated receptor-gamma ligands inhibit adipocyte 11beta -hydroxysteroid dehydrogenase type 1 expression and activity.

  The Journal of biological chemistry 20010420

• Using thiazolidinediones: rosiglitazone and pioglitazone in clinical practice.

  The American journal of managed care 20010401

• [Glitazones. Profile of a new class of substances].

  Der Internist 20010401

• Obesity and free fatty acids: double trouble.

  Nutrition, metabolism, and cardiovascular diseases : NMCD 20010401

• [Study on 3D-QSAR of PPAR gamma agonists with thiazolidinedione and arylketo-acid moieties].

  Yao xue xue bao = Acta pharmaceutica Sinica 20010401

• 2,4-Thiazolidinediones as potent and selective human beta3 agonists.

  Bioorganic & medicinal chemistry letters 20010326

• The transcription factor Fos-related antigen 1 is induced by thiazolidinediones during differentiation of 3T3-L1 cells.

  Molecular pharmacology 20010301

• Insulin resistance with enhanced insulin signaling in high-salt diet-fed rats.

  Diabetes 20010301

• Factors associated with the risk of liver enzyme elevation in patients with type 2 diabetes treated with a thiazolidinedione.

  Pharmacotherapy 20010201

• [Significance of PPAR gamma (peroxisome proliferator-activated receptor gamma) in atherosclerosis].

  Nihon rinsho. Japanese journal of clinical medicine 20010201

• PPAR gamma: an essential role in metabolic control.

  Nutrition, metabolism, and cardiovascular diseases : NMCD 20010201

• The hormone resistin links obesity to diabetes.

  Nature 20010118

• Thiazolidinediones (PPARgamma agonists) but not PPARalpha agonists increase IRS-2 gene expression in 3T3-L1 and human adipocytes.

  FASEB journal : official publication of the Federation of American Societies for Experimental Biology 20010101

• Thiazolidinedione- and tumor necrosis factor alpha-induced downregulation of peroxisome proliferator-activated receptor gamma mRNA in differentiated 3T3-L1 adipocytes.

  Metabolism: clinical and experimental 20010101

• Insulin resistance and its treatment by thiazolidinediones.

  Recent progress in hormone research 20010101

• Interaction between peroxisome proliferator-activated receptor gamma and its agonists: docking study of oximes having 5-benzyl-2,4-thiazolidinedione.

  Journal of molecular graphics & modelling 20010101

• Novel phthalazinone and benzoxazinone containing thiazolidinediones as antidiabetic and hypolipidemic agents.

  European journal of medicinal chemistry 20010101

• Hepatotoxicity with thiazolidinediones: is it a class effect?

  Drug safety 20010101

• Structure toxicity relationships--how useful are they in predicting toxicities of new drugs?

  Advances in experimental medicine and biology 20010101

• The effects of rexinoids and rosiglitazone on body weight and uncoupling protein isoform expression in the Zucker fa/fa rat.

  Metabolism: clinical and experimental 20001201

• Enhancing effect of troglitazone on porcine adipocyte differentiation in primary culture: a comparison with dexamethasone.

  Obesity research 20001201

• Down-regulation of uncoupling protein-3 and -2 by thiazolidinediones in C2C12 myotubes.

  FEBS letters 20001027

• Chronic and acute effects of thiazolidinediones BM13.1258 and BM15.2054 on rat skeletal muscle glucose metabolism.

  British journal of pharmacology 19991101

• L-764406 is a partial agonist of human peroxisome proliferator-activated receptor gamma. The role of Cys313 in ligand binding.

  The Journal of biological chemistry 19990319

• 1,25-Dihydroxy vitamin D3 inhibits adipocyte differentiation and gene expression in murine bone marrow stromal cell clones and primary cultures.

  Endocrinology 19980501